CD244 Monoclonal Antibody (eBioC1.7 (C1.7)), Functional Grade, eBioscience™, Invitrogen™

Description

• The eBioC1.7 MAb reacts with human CD244 (2B4, p38)
• In human, CD244 is a 38 kDa protein expressed on NK cells, a subset of CD8+ T cells, gammadelta T cells, monocytes, basophils and eosinophils
• Binding of the CD244 ligand, CD48, results in NK cell activation, unlike mouse CD244, which is an inhibitory receptor
• For CD244 expressed on NK cells, binding of CD48 results in enhanced NK cell cytotoxicity and secretion of IFN-gamma
• Recently, it was demonstrated that binding of the C1.7 MAb and CD48 involve the same residue in the V domain of human CD244, which explains the ability of C1.7 binding to induce activation of NK cells
• Binding of C1.7 to CD244 leads to tyrosine phosphorylation and recruitment of the adaptor molecule SAP (SLAM-associated protein)
• Patients with X-linked lymphoproliferative disorder (XLPD) have a mutation in SAP which renders it unable to bind to phosphorylated CD244
• CD244 (2B4, SLAMF4) is a cell surface receptor expressed on natural killer (NK) cells (and some T cells) that mediate non-major histocompatibility complex (MHC) restricted killing
• The interaction between NK-cell and target cells via CD244 is thought to modulate NK-cell cytolytic activity
• CD244 interacts with SLAMF2, causing the activation of both SLAMF4- and SLAMF2-expressing cells
• Patients with systemic lupus erythmatosus have lower than normal levels of SLAMF4 expressed on their NK cells and monocytes, suggesting that SLAMF4 may play a role in the pathology of this autoimmune disease
• Diseases associated with CD244 dysfunction include rheumatoid arthritis and lymphoproliferative syndrome
• Alternatively spliced transcript variants encoding different isoforms of CD244 have been found for this gene.